HOW WE CAN HELP
We offer our clients an extensive array of services designed specifically for the healthcare and life sciences sector. This includes expertise in capital raising, mergers and acquisitions, competition and consumer guidance, intellectual property and patents, Therapeutic Goods Regulation, as well as handling disputes and investigations. Our clients are diverse, ranging from government departments, agencies, and research bodies to private equity, large corporations in health and life sciences, venture capital firms, investors, and private health insurers. Within this sector, we specialise in the following:
- Pharmaceuticals, life sciences, and biotech: (Research and development, clinical trials, TGA compliance, manufacturing, regulatory affairs)
- Healthcare facilities and services: (Private and public hospitals, medical and dental practices, radiology, medical centres, aged care/NDIS and veterinary)
- MedTech and digital health platforms: (Artificial intelligence in healthcare technology, regulatory compliance)
- Aged sare and National Disability Insurance Scheme (NDIS) support
- Medical, surgical, and healthcare products: (Manufacturing and quality assurance, TGA compliance, logistics and distribution, retail and marketing).
On its merger with Chemist Warehouse Group. This merger will create Australia’s largest pharmacy group, with an expected market capitalisation of $8.8 billion.
On the $2.4 billion acquisition of Icon Group by EQT.
On IP and regulatory advice to a leading health services business on ground breaking weight loss medications.
On a joint venture with Sonic Healthcare to commercialise AI solutions in pathology.
On its $700 million acquisition by BGH Capital, marking a significant milestone in the fertility treatment industry amid a competitive takeover battle.
In court proceedings for breach of contract and misleading and deceptive conduct in relation to faulty ventilators supplied during the COVID-19 pandemic.
On the merger and competition compliance with Pfizer’s Upjohn division, creating a US $12 billion pharmaceutical giant.
On Infratil’s acquisition of up to 60% of Qscan Group Holdings, a prominent Australian diagnostic imaging practice, from Quadrant Private Equity and existing shareholders.
On multi-jurisdiction and high-stakes patent litigation addressing patent infringement allegations by Fisher & Paykel in Australia, the US, Germany, and New Zealand.
